Prediction of Motor Symptom Progression of Parkinson's Disease Through Multimodal Imaging-Based Machine Learning
- PMID: 40624388
- DOI: 10.1007/s10278-025-01583-7
Prediction of Motor Symptom Progression of Parkinson's Disease Through Multimodal Imaging-Based Machine Learning
Abstract
The unrelenting progression of Parkinson's disease (PD) leads to severely impaired quality of life, with considerable variability in progression rates among patients. Identifying biomarkers of PD progression could improve clinical monitoring and management. Radiomics, which facilitates data extraction from imaging for use in machine learning models, offers a promising approach to this challenge. This study investigated the use of multi-modality imaging, combining conventional magnetic resonance imaging (MRI) and dopamine transporter single photon emission computed tomography (DAT-SPECT), to predict motor progression in PD. Motor progression was measured by changes in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor subscale scores. Radiomic features were selected from the midbrain region in MRI and caudate nucleus, putamen, and ventral striatum in DAT-SPECT. Patients were stratified into fast progression vs. slow progression based on change in MDS-UPDRS in follow-up. Various feature selection methods and machine learning classifiers were evaluated for each modality, and the best-performing models were combined into an ensemble. On the internal test set, the ensemble model, which integrated clinical information, T1WI, T2WI and DAT-SPECT achieved a ROC AUC of 0.93 (95% CI: 0.80-1.00), PR AUC of 0.88 (95%CI 0.61-1.00), accuracy of 0.85 (95% CI: 0.70-0.89), sensitivity of 0.72 (95% CI: 0.43-1.00), and specificity of 0.92 (95% CI: 0.77-1.00). On the external test set, the ensemble model outperformed single-modality models with a ROC AUC of 0.77 (95% CI: 0.53-0.93), PR AUC of 0.79 (95% CI: 0.56-0.95), accuracy of 0.68 (95% CI: 0.50-0.86), sensitivity of 0.53 (95% CI: 0.27-0.82), and specificity of 0.82 (95% CI: 0.55-1.00). In conclusion, this study developed an imaging-based model to identify baseline characteristics predictive of disease progression in PD patients. The findings highlight the strength of using multiple imaging modalities and integrating imaging data with clinical information to enhance the prediction of motor progression in PD.
Keywords: DAT-SPECT; MRI; Machine learning; Motor symptom; Parkinson’s disease; Radiomic features.
© 2025. The Author(s) under exclusive licence to Society for Imaging Informatics in Medicine.
Conflict of interest statement
Declarations. Ethics Approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Johns Hopkins University (No. IRB00318113). Consent to Participate: For PPMI cohort, written informed consents and ethical declarations were available on the PPMI website ( http://www.ppmi-info.org ). For Institutional cohort, informed consent was obtained from all individual participants included in the study. Competing Interests: The authors declare no competing interests.
Similar articles
-
Machine learning-based brain magnetic resonance imaging radiomics for identifying rapid eye movement sleep behavior disorder in Parkinson's disease patients.BMC Med Imaging. 2025 Jul 1;25(1):227. doi: 10.1186/s12880-025-01748-4. BMC Med Imaging. 2025. PMID: 40597786 Free PMC article.
-
Machine learning-based radiomics for differentiating lung cancer subtypes in brain metastases using CE-T1WI.Front Oncol. 2025 Jun 19;15:1599882. doi: 10.3389/fonc.2025.1599882. eCollection 2025. Front Oncol. 2025. PMID: 40612349 Free PMC article.
-
Improving reliability of movement assessment in Parkinson's disease using computer vision-based automated severity estimation.J Parkinsons Dis. 2025 Mar;15(2):349-360. doi: 10.1177/1877718X241312605. Epub 2025 Feb 13. J Parkinsons Dis. 2025. PMID: 39973505
-
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2. Cochrane Database Syst Rev. 2012. PMID: 22419314 Free PMC article.
-
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.Adv Ther. 2021 Jun;38(6):2854-2890. doi: 10.1007/s12325-021-01747-1. Epub 2021 May 20. Adv Ther. 2021. PMID: 34018146 Free PMC article.
References
-
- Aryal S, Skinner T, Bridges B, Weber JT. The Pathology of Parkinson’s Disease and Potential Benefit of Dietary Polyphenols. Molecules. 2020;25(19).
Grants and funding
LinkOut - more resources
Research Materials
Miscellaneous